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Abstract
Introduction: Few cases of pulmonary toxicity related to epidermal growth factor receptor-targeted agents have
been described.
Case presentation: We report a case of a 63-year-old white male with stage IV non-small cell lung cancer treated
with erlotinib who developed a interstitial lung disease.
Conclusion: Respiratory symptoms during treatment with erlotinib should alert clinicians to rule out pulmonary
toxicity. Early erlotinib withdrawal and corticoid administration were successful.
Introduction
The human epidermal growth factor receptor (EGFR) is
a transmembrane glycoprotein that consists of an extra-
cellular ligand-binding domain, a hydrophobic trans-
membrane region, and an intracellular tyrosine kinase
domain [1]. The union with the ligand-binding activates
tyrosine-kinase and initiates a signalling cascade that
leads to cell proliferation, increased angiogenesis, metas-
tasis and decreased apoptosis [2]. Over-expression of
EGFR has been reported in a wide variety of solid
tumour types: lung, pancreatic, head and neck, colorec-
tal, breast, renal, glioma, prostate, ovarian and bladder
[1]. Epidermal growth factor receptor-targeted agents
have been investigated as second- and third-line treat-
ment [3]. The most developed agents in clinical research
are the intracellular EGFR tyrosine kinase inhibitors
(EGFR TKIs) (gefitinib, erlotinib) and the monoclonal
antibody aimed at extracellular ligand-binding domain
(cetuximab) [2]. Gefitinib (ZD1839, Iressa®; AstraZeneca)
has been approved for non-small cell lung cancer
(NSCLC), and erlotinib (OSI-774, CP-358,774, Tarceva®;
OSI Pharmaceuticals in collaboration with Genentech
and Roche Pharmaceuticals) has also been approved for
NSCLC and is in a Phase III trial in patients with pan-
creatic cancer. Adverse effects of gefitinib and erlotinib
are rash, diarrhea, asthenia and anorexia. Interstitial
lung disease (ILD) is an infrequent and usually fatal
complication [4]. We present a case of severe ILD in a
patient with NSCLC treated with erlotinib who survived.
Case Presentation
A 63-year-old non-smoker male presented with non-
productive cough and hypereosinophilia was finally diag-
nosed of stage IV NSCLC (T2aN2 M1) with visceral
involvement affecting contralateral lung, liver and brain.
Paraneoplastic hypereosinophilia was resolved with pre-
dnisone. Cisplatin and vinorelbine were given during
one month but needed withdrawal because of transient
acute renal insufficiency related to cisplatin. A second
line treatment with erlotinib (150 mg daily) in addition
to prednisone was initiated. Dramatic improvement of
symptoms and radiographic regression were induced.
After seven weeks of treatment fever and chills
appeared without demonstrable infection, coinciding
with reduction of the steroid dose from 20 mg to 1 mg/
day of prednisone. General conditions deteriorated in
the following seven days, and dyspnea, pulmonary infil-
trates and progressive respiratory failure developed (fig.
1). Computed Tomography showed increased interstitial
parenchyma density affecting both lungs (fig. 2). Heart
failure was also excluded: an echocardiography reported
normal ventricular chambers without dilatation nor
hypertrophia, no contractility impairment with left ven-
tricular ejection fraction 74%, normal atrial chambers
and no valve abnormalities. Erlotinib treatment was
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(1 mg/kg daily) was initiated. Empirical treatment with
imipenem, clarithromycin, trimethoprim - sulfamethoxa-
zole, amphotericin B and ganciclovir were given. Patient
was admitted in the Intensive Care Unit.
Despite therapy, the patient developed an acute lung
injury in accordance with the Lung Injury Score defini-
tions [5], and required mechanical ventilation with FiO2
0.6, tidal volume 450 ml, PEEP 10. Peak airway pressure
was 25 cm H2O and PaO2/FiO2 225. Cardiovascular
evaluation ruled out heart failure. Flexible fiberoptic
bronchofibroscopy revealed minimal inflammatory
changes. Bronchoalveolar lavage, protected catheter
brush and bronchial specimen cultures excluded acid-
fast resistant bacilli, bacterialo rf u n g a li n f e c t i o n s .E o s i -
nophilic pneumonitis and malignancy were also dis-
carded. Polymerase chain reaction analysis (PCR) for
Herpesviridae and Mycobacterium tuberculosis were per-
formed in blood and bronchial samples, proved also
negative. The Papanicolau stain in bronchoalveolar
lavage samples, and the hematoxylin-eosin stain in
transbronchial biospy samples discarded Pneumocystis
jiroveci infection. Blood and urine cultures were nega-
tive. Urinary antigen testing for Legionella and Pneumo-
coccus were also negative. Consequently, antibiotic
treatment was discontinued at day five.
On the following days gas-exchange improved and
pulmonary infiltrates progressively solved (fig. 3). It was
Figure 1 Diffuse bilateral interstitial infiltrates were predominant in upper lobes. Right hiliar consolidation corresponds to the tumor.
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was successfully extubated on the fourth day of intensive
care. On the sixth day he was discharged from the ICU
to a normal ward with the diagnosis of interstitial pneu-
monitis induced by erlotinib. Three months later a CT
scan was performed showing no abnormalities (fig. 4).
Discussion
ILD associated with gefitinib use has been reported in
approximately 1% of patients worldwide, with worse
evolution in current or former smokers and pre-exist-
ing pulmonary fibrosis [4,6]. There are few cases
reported of lung toxicity related to erlotinib use.
A phase III trial TRIBUTE, a randomized placebo-
controlled trial, examined the efficacy and safety of
erlotinib versus placebo in combination with paclitaxel
and carboplatin for first-line therapy of advanced
NSCLC in 1,079 patients. There were five severe ILD-
like events in the erlotinib arm (1.0%), versus one
event in the placebo arm (0.2%). All ILD-like events
were fatal [7]. There are two cases reported of ILD
induced by erlotinib treatment, one of them a 60-year-
old patient former smoker with previous pulmonary
fibrosis [4], the other one a 55-year-old current smoker
with chronic obstructive lung disease [8]. Both of them
died. After a review of all cases already published, we
report the case of a patient that survived after an
episode of severe ILD related to erlotinib.
Figure 2 Pulmonary CT scan shows extensive ground glass opacities.
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because of its potential increased mortality. High suspi-
cion is necessary in those patients under treatment with
erlotinib who develop respiratory symptoms like dys-
pnea, cough or fever. It is an exclusion diagnosis beyond
other possible causes like congestive heart failure, infec-
tion or lymphangitic carcinomatosis [8]. In our patient,
erlotinib withdrawal and corticotherapy (metilpredniso-
lone 1 mg/kg/day) were successful.
The etiology of ILD related to EGFR-tyrosine kinase
inhibitor therapy is poorly understood. Based on case
reports, common histopathologic evaluations have
revealed diffuse alveolar damage with hyaline membrane
formation. The molecular mechanisms leading to pul-
monary toxicity are also unclear [4].
Conclusion
In conclusion, clinicians should have a high suspicion
for the diagnosis of pulmonary toxicity when respiratory
symptoms appear in a patient while receiving erlotinib
treatment. Early withdrawal of erlotinib and treatment
with corticoids may improve prognosis. Further investi-
gation is necessary to establish if concomitant use of
corticoids and erlotinib can lower the incidence of pul-
monary toxicity associated to the EGFR-inhibitors treat-
ment. Research is necessary to determine the
Figure 3 (Six days later) important reduction of the bilateral infiltrates; previous consolidation is still present.
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opment of pulmonary toxicity related to erlotinib.
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Written informed consent was obtained from the patient
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